CRVS

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Corvus Pharmaceuticals Inc

NASDAQ | CRVS

5.92

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 18, 2025)

$431.44M

Market Cap

-

P/E Ratio

-1.1

EPS

$10.00

52 Week High

$2.54

52 Week Low

HEALTHCARE

Sector

CRVS Chart

Recent Chart
Price Action

CRVS Technicals

Tags:

CRVS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$85K
Total Revenue $0
Cost Of Revenue $85K
Costof Goods And Services Sold $85K
Operating Income -$28M
Selling General And Administrative $8.2M
Research And Development $19M
Operating Expenses $28M
Investment Income Net -
Net Interest Income $1.8M
Interest Income $1.8M
Interest Expense $1.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $33M
Income Before Tax -$62M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$62M
Comprehensive Income Net Of Tax -
Ebit -$60M
Ebitda -$28M
Net Income -$62M

Revenue & Profitability

Earnings Performance

CRVS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $69M
Total Current Assets $54M
Cash And Cash Equivalents At Carrying Value $8.7M
Cash And Short Term Investments $8.7M
Inventory -
Current Net Receivables $216K
Total Non Current Assets $15M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $13M
Short Term Investments $43M
Other Current Assets $2.2M
Other Non Current Assets -
Total Liabilities $36M
Total Current Liabilities $35M
Current Accounts Payable $2.6M
Deferred Revenue -
Current Debt -
Short Term Debt $370K
Total Non Current Liabilities $937K
Capital Lease Obligations $1.1M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.1M
Other Current Liabilities $32M
Other Non Current Liabilities -
Total Shareholder Equity $33M
Treasury Stock -
Retained Earnings -$397M
Common Stock $7K
Common Stock Shares Outstanding $61M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$25M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $85K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$27M
Cashflow From Financing $49M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$62M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$85K
Total Revenue $0
Cost Of Revenue $85K
Costof Goods And Services Sold $85K
Operating Income -$28M
Selling General And Administrative $8.2M
Research And Development $19M
Operating Expenses $28M
Investment Income Net -
Net Interest Income $1.8M
Interest Income $1.8M
Interest Expense $1.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $33M
Income Before Tax -$62M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$62M
Comprehensive Income Net Of Tax -
Ebit -$60M
Ebitda -$28M
Net Income -$62M

CRVS News

CRVS Profile

Corvus Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, dedicated to advancing innovative immuno-oncology therapies for the treatment of various cancers. Leveraging a robust pipeline of novel drug candidates, the company aims to harness the power of the immune system to improve patient outcomes in oncology. With a focus on precision medicine and strategic partnerships, Corvus is positioned to make significant contributions to the evolving landscape of cancer treatment.

ADAP
+85.76%
$0.15
INTC
+22.60%
$30.52
DVLT
+16.37%
$0.39
CGBS
-39.47%
$0.03
AERT
+62.33%
$0.92
GPUS
+24.67%
$0.51
BITF
+8.03%
$3.29
SNAP
+4.77%
$8.37
NVDA
+3.55%
$176.34
LASE
+62.17%
$4.54
APVO
+35.81%
$1.91
PLUG
+5.00%
$2.10
ATCH
-16.04%
$1.36
CDLX
+86.71%
$2.67
NEHC
-4.00%
$0.45
RGTI
+16.07%
$25.52
AAL
+0.44%
$12.53
TPIC
-45.91%
$0.12
ETNB
+85.26%
$14.96
AXDX
-61.36%
$0.03
RAYA
+20.35%
$0.05
SOUN
+5.39%
$15.93
NIO
-0.09%
$7.44
TSLA
-0.74%
$422.70
GRAB
+3.36%
$6.30
AMD
-2.16%
$155.71
BINI
-15.30%
$0.05
QBTS
+9.31%
$24.64
LYT
-16.77%
$0.09
BMNR
+5.27%
$60.08
YAAS
+8.45%
$0.07
PLTR
+5.21%
$177.11
SOFI
+5.12%
$28.53
MARA
+9.39%
$18.96
KDLY
-4.66%
$1.43
DNN
+0.79%
$2.56
CJET
+5.60%
$0.09
QS
+15.35%
$11.83
CLSK
+16.12%
$13.28
MULN
-6.96%
$0.06
VHAI
0.00%
$0.00
RMBL
+60.50%
$3.21
NFE
+21.12%
$2.61
ADD
-25.47%
$0.05
F
+0.51%
$11.72
BTG
-0.29%
$4.31
RR
+9.88%
$4.37
SRM
+53.27%
$10.30
QUBT
+6.04%
$18.78
TLRY
+4.24%
$1.24
BBD
-0.30%
$3.30
IONQ
+5.34%
$68.93
IXHL
+1.02%
$0.53
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BURU
+1.88%
$0.14
WLGS
-5.57%
$0.04
QSI
+29.36%
$1.63
RIVN
+5.03%
$14.82
HIMS
+11.48%
$56.13
NVNI
+12.58%
$0.90
BEEM
+18.37%
$2.99
ONDS
+5.00%
$6.40
ETWO
0.00%
$3.30
AAPL
-0.47%
$237.85
ORIS
+15.69%
$0.16
HOOD
+3.81%
$123.16
ABEV
-2.11%
$2.31
IONZ
-10.62%
$4.28
NOK
+1.16%
$4.75
JOBY
+3.31%
$14.62
CIFR
-5.68%
$11.67
PBM
+29.56%
$4.82
WBD
+1.29%
$18.22
AFMD
-34.94%
$0.18
ACHR
+2.59%
$9.23
NAKA
+1.73%
$1.45
KEY
+1.63%
$19.01
LDI
-10.41%
$4.08
FAAS
-13.30%
$0.07
RIOT
+1.26%
$17.84
SBET
+3.62%
$17.73
AMZN
+0.30%
$232.32
AQB
+22.80%
$1.40
BTE
-2.53%
$2.48
OKLO
+14.68%
$109.28
UEC
-1.90%
$12.00
OPI
-24.11%
$0.43
WULF
-1.14%
$11.22
NVTS
+5.88%
$6.84
HBAN
+1.53%
$17.80
BAC
+0.82%
$51.82
ITUB
-0.20%
$7.25
AIRE
-7.22%
$1.15
PFE
+0.60%
$24.19
CAN
+1.79%
$0.82
REPL
-43.16%
$3.24
IREN
-3.11%
$36.72
GRYP
-10.38%
$1.38
MU
+5.48%
$168.77
ADAP
+85.76%
$0.15
INTC
+22.60%
$30.52
DVLT
+16.37%
$0.39
CGBS
-39.47%
$0.03
AERT
+62.33%
$0.92
GPUS
+24.67%
$0.51
BITF
+8.03%
$3.29
SNAP
+4.77%
$8.37
NVDA
+3.55%
$176.34
LASE
+62.17%
$4.54
APVO
+35.81%
$1.91
PLUG
+5.00%
$2.10
ATCH
-16.04%
$1.36
CDLX
+86.71%
$2.67
NEHC
-4.00%
$0.45
RGTI
+16.07%
$25.52
AAL
+0.44%
$12.53
TPIC
-45.91%
$0.12
ETNB
+85.26%
$14.96
AXDX
-61.36%
$0.03
RAYA
+20.35%
$0.05
SOUN
+5.39%
$15.93
NIO
-0.09%
$7.44
TSLA
-0.74%
$422.70
GRAB
+3.36%
$6.30
AMD
-2.16%
$155.71
BINI
-15.30%
$0.05
QBTS
+9.31%
$24.64
LYT
-16.77%
$0.09
BMNR
+5.27%
$60.08
YAAS
+8.45%
$0.07
PLTR
+5.21%
$177.11
SOFI
+5.12%
$28.53
MARA
+9.39%
$18.96
KDLY
-4.66%
$1.43
DNN
+0.79%
$2.56
CJET
+5.60%
$0.09
QS
+15.35%
$11.83
CLSK
+16.12%
$13.28
MULN
-6.96%
$0.06
VHAI
0.00%
$0.00
RMBL
+60.50%
$3.21
NFE
+21.12%
$2.61
ADD
-25.47%
$0.05
F
+0.51%
$11.72
BTG
-0.29%
$4.31
RR
+9.88%
$4.37
SRM
+53.27%
$10.30
QUBT
+6.04%
$18.78
TLRY
+4.24%
$1.24
BBD
-0.30%
$3.30
IONQ
+5.34%
$68.93
IXHL
+1.02%
$0.53
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BURU
+1.88%
$0.14
WLGS
-5.57%
$0.04
QSI
+29.36%
$1.63
RIVN
+5.03%
$14.82
HIMS
+11.48%
$56.13
NVNI
+12.58%
$0.90
BEEM
+18.37%
$2.99
ONDS
+5.00%
$6.40
ETWO
0.00%
$3.30
AAPL
-0.47%
$237.85
ORIS
+15.69%
$0.16
HOOD
+3.81%
$123.16
ABEV
-2.11%
$2.31
IONZ
-10.62%
$4.28
NOK
+1.16%
$4.75
JOBY
+3.31%
$14.62
CIFR
-5.68%
$11.67
PBM
+29.56%
$4.82
WBD
+1.29%
$18.22
AFMD
-34.94%
$0.18
ACHR
+2.59%
$9.23
NAKA
+1.73%
$1.45
KEY
+1.63%
$19.01
LDI
-10.41%
$4.08
FAAS
-13.30%
$0.07
RIOT
+1.26%
$17.84
SBET
+3.62%
$17.73
AMZN
+0.30%
$232.32
AQB
+22.80%
$1.40
BTE
-2.53%
$2.48
OKLO
+14.68%
$109.28
UEC
-1.90%
$12.00
OPI
-24.11%
$0.43
WULF
-1.14%
$11.22
NVTS
+5.88%
$6.84
HBAN
+1.53%
$17.80
BAC
+0.82%
$51.82
ITUB
-0.20%
$7.25
AIRE
-7.22%
$1.15
PFE
+0.60%
$24.19
CAN
+1.79%
$0.82
REPL
-43.16%
$3.24
IREN
-3.11%
$36.72
GRYP
-10.38%
$1.38
MU
+5.48%
$168.77
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.